Tag: capsid tropism screening platforms market forecast

  • Capsid Tropism Screening Platforms Market Outlook From 2026 To 2030: Key Growth Factors And Future Opportunities

    Capsid Tropism Screening Platforms Market Outlook From 2026 To 2030: Key Growth Factors And Future Opportunities

    Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

    Capsid Tropism Screening Platforms Market Growth Potential: How Will Market Size Shift Through 2030?

    The market size for capsid tropism screening platforms has seen rapid expansion in recent years. This market is expected to increase from $0.74 billion in 2025 to $0.85 billion in 2026, at a compound annual growth rate (CAGR) of 14.2%. The development observed in previous periods can be linked to increasing investment in gene therapy research, growing demand for viral vector optimization, adoption of flow cytometry and sequencing technologies, rising focus on personalized medicine, and expansion of pharmaceutical and biotech R&D infrastructure.

    The capsid tropism screening platforms market is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.45 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. This projected growth can be attributed to several factors, including the increasing application of AI-driven capsid tropism analysis, the broader adoption of high-content imaging and microfluidics, a rising demand for single-cell sequencing and sophisticated screening platforms, the expansion of contract research organizations (CROs), and the enhanced integration of multiplex assay and digital PCR technologies. Furthermore, key trends for the forecast period include the increasing uptake of high-throughput screening platforms, an escalating demand for next-generation sequencing solutions, the wider integration of flow cytometry technologies, an expansion in the available assay kits and reagent offerings, and a heightened focus on gene therapy and vaccine development applications.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=46680568&type=smp&name=Capsid%20Tropism%20Screening%20Platforms%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Capsid Tropism Screening Platforms Market Growth Catalysts And Demand Drivers

    The heightened demand for targeted gene therapies is projected to fuel the expansion of the capsid tropism screening platforms market throughout the forecast period. These therapies focus on delivering therapeutic genetic material precisely to specific cells or tissues, aiming to correct, alter, or substitute flawed genes linked to illnesses. Several factors contribute to this escalating demand, such as the increasing occurrence of genetic and rare diseases, progress in vector engineering technologies, and greater investment in precision medicine strategies designed to enhance treatment effectiveness while reducing unintended side effects. Capsid tropism screening platforms are crucial in gene therapy development, as they facilitate the systematic assessment and selection of viral vectors that exhibit ideal tissue and cell specificity. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, representing the first quarterly increase since the third quarter of 2022. Consequently, the growing need for targeted gene therapies is a significant driver for the growth of the capsid tropism screening platforms market.

    Capsid Tropism Screening Platforms Market Breakdown By Product Type And Application

    The capsid tropism screening platforms market covered in this report is segmented –

    1) By Technology: High-Throughput Screening, Next-Generation Sequencing, Flow Cytometry, Other Technologies

    2) By Product Type: Assay Kits, Reagents, Instruments, Software, Services

    3) By Application: Gene Therapy Development, Vaccine Development, Drug Discovery, Other Applications

    4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-Users

    Subsegments:

    1) By High-Throughput Screening: Cell-Based Screening, Biochemical Screening, High-Content Screening, Automated Screening, Label-Free Screening

    2) By Next-Generation Sequencing: Short-Read Sequencing, Long-Read Sequencing, Targeted Sequencing, Whole-Genome Sequencing, Single-Cell Sequencing

    3) By Flow Cytometry: Conventional Flow Cytometry, Spectral Flow Cytometry, Imaging Flow Cytometry, Cell Sorting, Mass Cytometry

    4) By Other Technologies: Microfluidics-Based Screening, High-Content Imaging, Mass Spectrometry, Polymerase Chain Reaction And Digital Polymerase Chain Reaction, Immunoassay-Based Platforms

    Capsid Tropism Screening Platforms Market Trends Shaping Long-Term Demand

    Leading companies operating within the capsid tropism screening platforms market are forging strategic alliances to create innovative high-throughput and barcoded adeno-associated virus screening solutions. These strategic partnerships stimulate the expansion of the capsid tropism screening platforms market by facilitating the collaborative advancement of sophisticated adeno-associated virus screening technologies, diversifying product ranges, and expediting gene therapy research and its market entry. For example, in August 2025, PackGene Biotech Inc., a US-based biotechnology company, finalized a strategic licensing agreement with the Children’s Medical Research Institute (CMRI), an Australia-based independent organization, to commercialize barcoded high-throughput adeno-associated virus capsid screening kits. These kits empower researchers to swiftly assess multiple adeno-associated virus capsid variants simultaneously, leveraging a barcode system and next-generation sequencing. The aim of this collaboration is to accelerate gene therapy development through optimized capsid selection and improved access to advanced screening instruments.

    Capsid Tropism Screening Platforms Market Key Participants And Competitive Landscape

    Major companies operating in the capsid tropism screening platforms market are Sarepta Therapeutics Inc., Voyager Therapeutics Inc., Bluebird Bio Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., MeiraGTx Holdings plc, Dyno Therapeutics Inc., 4D Molecular Therapeutics Inc., Asklepios BioPharmaceutical Inc., PackGene Biotech Inc., Creative Biolabs Inc., VectorBuilder Inc., uniQure N.V., Homology Medicines Inc., Capsida Biotherapeutics Inc., LogicBio Therapeutics Inc., Capsigen Inc., GeneMedi Inc., Spark Therapeutics Inc., Creative Biogene Inc.

    View The Full Capsid Tropism Screening Platforms Market Report:

    https://thebusinessresearchcompany.com/report/capsid-tropism-screening-platforms-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Capsid Tropism Screening Platforms Market Geographic Analysis: Where Is Demand Rising Fastest?

    North America was the largest region in the capsid tropism screening platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the capsid tropism screening platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Capsid Tropism Screening Platforms Market Outlook Featuring Demand Trends And Future Growth Potential

    Capsid Tropism Screening Platforms Market Outlook Featuring Demand Trends And Future Growth Potential

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Capsid Tropism Screening Platforms Market During 2026–2030?

    In recent years, the capsid tropism screening platforms market size has experienced swift expansion. It is projected to increase from $0.74 billion in 2025 to $0.85 billion in 2026, at a compound annual growth rate (CAGR) of 14.2%. The historical growth can be ascribed to escalating investment in gene therapy research, the rising demand for viral vector optimization, the adoption of flow cytometry and sequencing technologies, a heightened focus on personalized medicine, and the expansion of pharmaceutical and biotech R&D infrastructure.

    The market size for capsid tropism screening platforms is anticipated to experience swift expansion over the next few years. It is projected to achieve a value of $1.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.4%. This growth during the forecast period is attributable to the increasing application of AI-driven capsid tropism analysis, the expanding use of high-content imaging and microfluidics, a surging demand for single-cell sequencing and advanced screening platforms, the enlargement of contract research organizations (CROs), and the greater integration of multiplex assay and digital PCR technologies. Significant trends for the forecast period include the increasing adoption of high-throughput screening platforms, a rising demand for next-generation sequencing solutions, the growing integration of flow cytometry technologies, the expansion of assay kits and reagent product lines, and an elevated focus on applications in gene therapy and vaccine development.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample_request?id=65623372&type=smp&name=Capsid%20Tropism%20Screening%20Platforms%20Market%20Report%202026

    Which Factors Are Influencing The Growth Of The Capsid Tropism Screening Platforms Market?

    The escalating demand for targeted gene therapies is projected to propel the expansion of the capsid tropism screening platforms market throughout the forecast period. These specialized gene therapies focus on delivering therapeutic genetic material to specific cells or tissues to correct, modify, or replace defective genes associated with disease. The increasing need for such therapies is fueled by several factors, including the rising prevalence of genetic and rare diseases, advancements in vector engineering technologies, and augmented investment in precision medicine approaches aimed at enhancing treatment efficacy while minimizing off-target effects. Capsid tropism screening platforms are pivotal in gene therapy development, allowing for the systematic evaluation and selection of viral vectors with optimal tissue and cell specificity. For instance, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, reported that the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Therefore, the growing demand for targeted gene therapies is a key driver for the growth of the capsid tropism screening platforms market.

    How Is The Capsid Tropism Screening Platforms Market Broken Down By Segment Categories?

    The capsid tropism screening platforms market covered in this report is segmented –

    1) By Technology: High-Throughput Screening, Next-Generation Sequencing, Flow Cytometry, Other Technologies

    2) By Product Type: Assay Kits, Reagents, Instruments, Software, Services

    3) By Application: Gene Therapy Development, Vaccine Development, Drug Discovery, Other Applications

    4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-Users

    Subsegments:

    1) By High-Throughput Screening: Cell-Based Screening, Biochemical Screening, High-Content Screening, Automated Screening, Label-Free Screening

    2) By Next-Generation Sequencing: Short-Read Sequencing, Long-Read Sequencing, Targeted Sequencing, Whole-Genome Sequencing, Single-Cell Sequencing

    3) By Flow Cytometry: Conventional Flow Cytometry, Spectral Flow Cytometry, Imaging Flow Cytometry, Cell Sorting, Mass Cytometry

    4) By Other Technologies: Microfluidics-Based Screening, High-Content Imaging, Mass Spectrometry, Polymerase Chain Reaction And Digital Polymerase Chain Reaction, Immunoassay-Based Platforms

    What Trends Are Transforming The Capsid Tropism Screening Platforms Market?

    Leading companies in the capsid tropism screening platforms market are entering into strategic partnerships to develop innovative high-throughput and barcoded adeno-associated virus screening solutions. These strategic alliances drive the growth of the capsid tropism screening platforms market by fostering collaborative advancement of sophisticated adeno-associated virus screening technologies, expanding product ranges, and accelerating both gene therapy research and its commercialization. For instance, in August 2025, PackGene Biotech Inc., a US-based biotechnology company, finalized a strategic licensing agreement with the Children’s Medical Research Institute (CMRI), an Australia-based independent organization, with the aim of commercializing barcoded high-throughput adeno-associated virus capsid screening kits. These kits enable researchers to rapidly evaluate numerous adeno-associated virus capsid variants simultaneously through the use of a barcode system and next-generation sequencing. The collaboration’s goal is to expedite gene therapy development by simplifying capsid selection and enhancing access to advanced screening instruments.

    Which Players Are Present In The Capsid Tropism Screening Platforms Market Space?

    Major companies operating in the capsid tropism screening platforms market are Sarepta Therapeutics Inc., Voyager Therapeutics Inc., Bluebird Bio Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., MeiraGTx Holdings plc, Dyno Therapeutics Inc., 4D Molecular Therapeutics Inc., Asklepios BioPharmaceutical Inc., PackGene Biotech Inc., Creative Biolabs Inc., VectorBuilder Inc., uniQure N.V., Homology Medicines Inc., Capsida Biotherapeutics Inc., LogicBio Therapeutics Inc., Capsigen Inc., GeneMedi Inc., Spark Therapeutics Inc., Creative Biogene Inc.

    Get The Full Capsid Tropism Screening Platforms Market Report:

    https://www.thebusinessresearchcompany.com/report/capsid-tropism-screening-platforms-market-report

    Which Region Is The Leading Market For The Capsid Tropism Screening Platforms Market?

    North America was the largest region in the capsid tropism screening platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the capsid tropism screening platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Capsid Tropism Screening Platforms Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/Customise?id=65623372&name=Capsid%20Tropism%20Screening%20Platforms%20Market%20Report%202026&type=smp

    Browse Through More Reports Similar to the Global Capsid Tropism Screening Platforms Market 2026, By The Business Research Company

    adeno-associated virus (avv) vectors in gene therapy market report 2026

    https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

    gastric cancer therapy market report 2026

    https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

    over the counter (otc) drugs market report 2026

    https://www.thebusinessresearchcompany.com/report/over-the-counter-otc-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model